Medtronic Receives FDA Breakthrough Designation for the Emprint Ablation Catheter Kit
Minimally Invasive Option Has Potential to Provide Long-Term Management of Lung Malignancies While Protecting Lung Function Medtronic plc the global leader in medical technology, today announced it has received Breakthrough Device Designation status from the U.S. Food and Drug Administration for the Emprint™ ablation catheter kit an investigational device not yet approved or cleared in the United States . The …
Minimally Invasive Option Has Potential to Provide Long-Term Management of Lung Malignancies While Protecting Lung Function
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the Emprint™ ablation catheter kit an investigational device not yet approved or cleared in the United States . The catheter is intended to be used in conjunction with the Emprint™ microwave generator and Medtronic lung navigation platform to provide a minimally invasive, localized treatment of malignant lesions in the lung, and it can be used together with standard of care therapy when indicated.